PfizerPFE
About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Employees: 81,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
5% more funds holding in top 10
Funds holding in top 10: 41 [Q4 2024] → 43 (+2) [Q1 2025]
8% more repeat investments, than reductions
Existing positions increased: 1,261 | Existing positions reduced: 1,170
5% less capital invested
Capital invested by funds: $99.7B [Q4 2024] → $94.8B (-$4.89B) [Q1 2025]
6% less first-time investments, than exits
New positions opened: 176 | Existing positions closed: 187
1.52% less ownership
Funds ownership: 65.97% [Q4 2024] → 64.45% (-1.52%) [Q1 2025]
3% less funds holding
Funds holding: 2,944 [Q4 2024] → 2,868 (-76) [Q1 2025]
23% less call options, than puts
Call options by funds: $2.97B | Put options by funds: $3.87B
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
UBS Trung Huynh | 3%downside $25 | Neutral Maintained | 30 Apr 2025 |
Cantor Fitzgerald Carter Gould | 6%downside $24 | Neutral Initiated | 22 Apr 2025 |
Financial journalist opinion
Based on 75 articles about PFE published over the past 30 days
